Alimera Sciences Inc (ALIM.O)
19 Dec 2014
|Market Cap (Mil.):||$256.92|
|Shares Outstanding (Mil.):||44.30|
- Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections.
Sept 26 - Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections.
Sept 26 - The Food and Drug Administration has approved Alimera Sciences Inc's and pSivida Corp's vision-loss treatment Iluvien after three rejections.
|Novartis AG (NOVN.VX)||CHF92.35||-1.20|
|Roche Holding Ltd. (ROG.VX)||CHF270.10||-3.20|
|Bayer AG (BAYGn.DE)||€115.20||-0.20|
|Bayer AG (BAYE.F)||--||--|
|Allergan, Inc. (AGN.N)||$212.63||+0.45|
|Regeneron Pharmaceuticals Inc (REGN.OQ)||$413.48||+13.36|
|ThromboGenics NV (THR.BR)||€6.55||+0.05|
|pSivida Corp. (PSDV.OQ)||$4.02||+0.02|
|Ampio Pharmaceuticals Inc (AMPE.A)||$3.44||+0.01|
|Ophthotech Corp (OPHT.OQ)||$45.03||+0.10|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Trading Report for (ALIM). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ALIMERA SCIENCES INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
"The Economy Matters" Report for ALIM: the economy's impact on ALIM's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
Alimera Sciences Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.